Method of detecting bladder cancer
AssigneesSbi Alapromo Co., Ltd., Kochi Unversity
InventorsKeiji Inoue, Masahiro Ishizuka
Life of this patent
Estimating the term…
Loading patent…
AssigneesSbi Alapromo Co., Ltd., Kochi Unversity
InventorsKeiji Inoue, Masahiro Ishizuka
Estimating the term…
Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
A sensitizer which is an orally administered agent for detecting bladder cancer and which comprises 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these.
A sensitizer which is an intravenously injected agent for detecting bladder cancer and which comprises 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these.
A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing a sensitizer which is an orally administered agent for detecting bladder cancer.
A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing a sensitizer which is an intravenously injected agent for detecting bladder cancer.
Dependencies are inferred from the claim text.